[Federal Register Volume 76, Number 135 (Thursday, July 14, 2011)]
[Proposed Rules]
[Pages 41434-41438]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2011-17696]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Part 203

[Docket No. FDA-2011-N-0446]


Removal of Certain Requirements Related to the Prescription Drug 
Marketing Act; Opportunity for Public Comment

AGENCY: Food and Drug Administration, HHS.

ACTION: Proposed rule.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is proposing to remove 
a section of the Prescription Drug Marketing Act (PDMA) regulations 
requiring that prior to the completion of any wholesale distribution of 
a prescription drug, an unauthorized distributor must provide to the 
purchaser ``a statement identifying each prior sale, purchase, or trade 
of such drug,'' starting with the manufacturer, and that the 
identifying statement (also known as the ``pedigree'') must include 
certain information about the drug and each prior sale, purchase, or 
trade. This action is being taken in response to longstanding issues, 
including an injunction currently in effect, regarding the application 
of and compliance with this requirement. FDA is also announcing that it 
intends to exercise enforcement discretion with respect to certain 
requirements of the regulation while the rulemaking is pending and with 
respect to the statutory pedigree requirements of the PDMA, as long as 
the pedigree identifies the names and addresses of the last authorized 
distributor of record that handled the drug and the associated dates of 
transactions involving that last authorized distributor of record and 
the drug, as well as the names and addresses of all subsequent 
unauthorized distributors that handled the drug and the corresponding 
dates of those transactions.

DATES: Submit either electronic or written comments on the proposed 
rule by September 12, 2011.

ADDRESSES: You may submit comments, identified by Docket No. FDA-2011-
N-0446, by any of the following methods:

Electronic Submissions

    Submit electronic comments in the following way:
     Federal eRulemaking Portal: http://www.regulations.gov. 
Follow the instructions for submitting comments.

[[Page 41435]]

Written Submissions

    Submit written submissions in the following ways:
     FAX: 301-827-6870.
     Mail/Hand delivery/Courier (for paper, disk, or CD-ROM 
submissions): Division of Dockets Management (HFA-305), Food and Drug 
Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852.
    Instructions: All submissions received must include the Agency name 
and Docket No. for this rulemaking. All comments received may be posted 
without change to http://www.regulations.gov, including any personal 
information provided. For additional information on submitting 
comments, see the ``Comments'' heading of the SUPPLEMENTARY INFORMATION 
section of this document.
    Docket: For access to the docket to read background documents or 
comments received, go to http://www.regulations.gov and insert the 
docket number(s), found in brackets in the heading of this document, 
into the ``Search'' box and follow the prompts and/or go to the 
Division of Dockets Management, 5630 Fishers Lane, rm. 1061, Rockville, 
MD 20852.

FOR FURTHER INFORMATION CONTACT: Karen Rothschild, Center for Drug 
Evaluation and Research, Food Drug Administration, 10903 New Hampshire 
Ave., Silver Spring, MD 20993, 301-796-3689, e-mail: 
[email protected].

SUPPLEMENTARY INFORMATION:

I. Background

    The PDMA (Pub. L. 100-293) was enacted on April 22, 1988, and was 
modified by the PDA (Pub. L. 102-353) on August 26, 1992. The PDMA, as 
modified, amended the Federal Food, Drug, and Cosmetic Act (the FD&C 
Act) to establish restrictions and requirements relating to various 
aspects of human prescription drug marketing and distribution. The 
primary purpose of the PDMA was to increase safeguards to prevent the 
introduction and retail sale of substandard, ineffective, and 
counterfeit drugs into the U.S. drug supply chain. Among other things, 
the PDMA, in section 503(e)(1)(A) of the FD&C Act (21 U.S.C. 353), 
requires a wholesale distributor ``who is not the manufacturer or 
authorized distributor of record'' to provide drug pedigrees to 
purchasers ``identifying each prior sale, purchase or trade of such 
drug (including the date of the transaction and the names and addresses 
of all parties to the transaction).''
    On August 1, 1988, the Agency issued a letter that provided 
guidance on the PDMA for industry pending the issuance of implementing 
regulations (the 1988 guidance letter) (see attachment E of FDA's 2001 
Report to Congress (http://www.fda.gov/downloads/RegulatoryInformation/Legislation/FederalFoodDrugandCosmeticActFDCAct/SignificantAmendmentstotheFDCAct/PrescriptionDrugMarketingActof1987/UCM203186.pdf)). Among other issues, the 1988 guidance letter discussed 
drug pedigrees. The 1988 guidance letter stated that the necessary 
identifying information regarding all sales in the chain of 
distribution may start with the manufacturer or authorized distributor 
of record. As explained in an FDA 2001 Prescription Drug Marketing Act 
Report to Congress (2001 Report to Congress) (see http://www.fda.gov/downloads/RegulatoryInformation/Legislation/FederalFoodDrugandCosmeticActFDCAct/SignificantAmendmentstotheFDCAct/PrescriptionDrugMarketingActof1987/UCM203186.pdf), it was the Agency's 
understanding at the time that the authorized distributor of record 
would be the distributor to whom the manufacturer first sold the drugs, 
not just any authorized distributor who happened to purchase the drugs 
somewhere along the distribution chain.
    In the Federal Register of March 14, 1994 (59 FR 11842), we issued 
a proposed rule related to certain provisions of the PDMA. With respect 
to prescription drug pedigrees, the proposed rule provided in relevant 
part that the identifying statement for sales by unauthorized 
distributors must include ``the business name and address of all 
parties to each prior transaction involving the drug, starting with the 
manufacturer.'' (59 FR 11865). A final rule was issued in the Federal 
Register of December 3, 1999 (64 FR 67720) (the December 1999 final 
rule), with an effective date of December 4, 2000. The final rule 
contained provisions on prescription drug reimportation; wholesale 
distribution of prescription drugs by unauthorized distributors; the 
resale of prescription drugs by hospitals, health care entities, and 
charitable institutions; and distribution of prescription drug samples. 
In the December 1999 final rule, FDA responded to a comment objecting 
to the pedigree requirement as proposed because it would require an 
unauthorized distributor to provide information about all prior sales, 
purchases, or trades of the drug, starting with the manufacturer, even 
in cases where the seller from whom the distributor received the drug 
was an authorized distributor of record and did not provide any 
pedigree for the drug. The comment recommended revising the proposed 
rule to require that the pedigree only go back to the last authorized 
distributor of record (64 FR 67720 at 67747). FDA declined to revise 
the rule, explaining that the statute requires that the pedigree 
identify ``each prior sale, purchase, or trade of the drug'' and 
``[t]here is no indication in [the] PDMA that Congress intended that 
the statement include only those sales, purchases, or trades since the 
drug was last handled by an authorized distributor.'' (64 FR 67720 at 
67747).
    The December 1999 final rule thus codified Sec.  203.50(a) (21 CFR 
203.50(a)), which follows section 503(e)(1)(A) of the FD&C Act, 
requiring that, before the completion of any wholesale distribution by 
a wholesale distributor of a prescription drug for which the seller is 
not a manufacturer or an authorized distributor of record, the seller 
must provide to the purchaser a statement (also referred to as a 
pedigree) identifying each prior sale, purchase, or trade of the drug. 
According to Sec.  203.50(a), the identifying statement must include: 
The proprietary and established name of the drug; dosage; container 
size; number of containers; the lot or control numbers of the drug 
being distributed; the business name and address of all parties to each 
prior transaction involving the drug, starting with the manufacturer; 
and the date of each previous transaction.
    After publication of the December 1999 final rule, we received many 
comments on, and held several meetings to discuss, the implications of 
the final regulations regarding, among other things, the pedigree 
provisions at Sec.  203.50(a) requiring unauthorized distributors to 
provide a pedigree showing all prior sales going back to the 
manufacturer. Industry representatives of unauthorized distributors 
represented that they could not obtain the required pedigree showing 
all prior sales of the drugs they purchase because a large portion of 
these drugs are purchased from authorized distributors who are not 
required to provide pedigrees and who are unwilling to voluntarily 
provide them.\1\ Industry representatives also claimed that 
implementation of this requirement could prevent as many as 4,000 
smaller, unauthorized distributors from distributing many drugs to 
their

[[Page 41436]]

customers, putting the unauthorized distributors out of business.\2\
---------------------------------------------------------------------------

    \1\ FDA, The Prescription Drug Marketing Act Report to Congress, 
2001 (http://www.fda.gov/downloads/RegulatoryInformation/Legislation/FederalFoodDrugandCosmeticActFDCAct/SignificantAmendmentstotheFDCAct/PrescriptionDrugMarketingActof1987/UCM203186.pdf).
    \2\ (See footnote 1 of this document.)
---------------------------------------------------------------------------

    In the 2001 Report to Congress, we noted that we would be able to 
address some, but not all of the concerns raised by unauthorized 
distributors. We stated that we believed that ``the concerns related to 
continuing to exempt authorized distributors from the pedigree 
requirement and the exact meaning of the phrase `each prior sale' can 
be addressed only through statutory remedies.'' \3\
---------------------------------------------------------------------------

    \3\ (See footnote 1 of this document.)
---------------------------------------------------------------------------

    As a result of these comments, other informal communications that 
FDA had with industry, industry associations, and Congress, and the 
Agency's consideration of a petition for stay of action received on May 
3, 2000, FDA delayed the effective date of several provisions of the 
December 1999 final rule until October 1, 2001, and reopened the 
administrative record to receive additional comments (65 FR 25639, May 
3, 2000). In the Federal Register of March 1, 2001 (66 FR 12850), we 
announced our decision to further delay until April 1, 2002, the 
applicability of Sec.  203.50, among other provisions. Further delays 
of the effective dates followed until December 1, 2006, to give us 
additional time to consider whether regulatory changes were appropriate 
and, if so, to initiate such changes (67 FR 6645, February 13, 2002; 69 
FR 4912, January 23, 2003; 69 FR 8105, February 23, 2004).
    While Sec.  203.50 was stayed, the industry followed the advice 
given in the 1988 guidance letter, which, as noted previously, stated 
that the pedigree should include ``all necessary identifying 
information regarding all sales in the chain of distribution of the 
product, starting with the manufacturer or the authorized 
distributor.''
    In the Federal Register of June 14, 2006 (71 FR 34249), we 
announced that FDA did not intend to further delay the effective date 
of certain regulations related to the PDMA, including Sec.  203.50, and 
that the regulation would go into effect on December 1, 2006.
    On September 20, 2006, a group of unauthorized wholesalers of 
prescription drugs filed a lawsuit against FDA in the U.S. District 
Court for the Eastern District of New York, seeking, among other 
things, a declaratory judgment that Sec.  203.50(a) erroneously 
interprets the statutory requirement for pedigrees (21 U.S.C. 
353(e)(1)(A)), and violates the U.S. Constitution's guarantees of equal 
protection and due process. (RxUSA Wholesale, Inc. v. Dept. of Health 
and Human Servs., 467 F. Supp.2d 285 (E.D.N.Y. 2006)). On November 22, 
2006, the plaintiffs moved for a preliminary injunction against 
implementation of the regulation, which, as noted previously, was 
scheduled to become effective on December 1, 2006. On December 8, 2006, 
the district court issued a preliminary injunction enjoining FDA from 
implementing Sec.  203.50(a) (467 F.Supp. 2d at 292). The court 
concluded that the statute, unlike Sec.  203.50(a), does not 
``specifically or expressly require[] unauthorized distributors to 
provide pedigree information all the way back to the manufacturer.'' 
467 F. Supp. 2d at 290 (emphasis in original). The court stated that 
``[u]nauthorized distributors would be unable to comply with'' the 
December 1999 final rule requirement to ``provide complete pedigree 
information for all prior sales up to the manufacturer'' because 
unauthorized distributors purchase drugs from authorized distributors 
``who do not provide pedigree information.'' (467 F. Supp. 2d at 291). 
The district court concluded that plaintiffs had shown a likelihood of 
success on the merits of their claim because, in the court's view, the 
pedigree regulation undermined the purpose of the statute and was 
therefore arbitrary and capricious. (467 F. Supp. 2d at 291). The court 
also found that issuance of the preliminary injunction would benefit 
the public interest by preserving ``the status quo and the current 
practice in the industry.'' (467 F. Supp. 2d at 292).
    The Agency appealed the district court's preliminary injunction 
order, but the district court's order was affirmed on July 10, 2008, by 
the U.S. Court of Appeals for the Second Circuit. (See RxUSA Wholesale, 
Inc., v. Dept. of Health and Human Servs., 285 Fed. Appx. 809 (2d Cir. 
2008)). The appellate court explained that the PDMA ``does not 
specifically state whether'' a pedigree must ``extend back to the 
manufacturer, or whether it must only extend to the last authorized 
distributor. The parties offer differing textual interpretations, but 
we agree with the district court that for purposes of preliminary 
injunction the statute's language does not unambiguously compel one 
interpretation over another.'' (285 Fed. Appx. at 811). Moreover, the 
second circuit concluded that the district court had not abused its 
discretion in determining that the plaintiffs had shown a likelihood of 
success on the merits because Sec.  203.50(a) requires unauthorized 
distributors to ``provide pedigree information that is currently held 
only by authorized distributors'' and the regulation is ``inconsistent 
with the position taken by the agency in its original 1988 guidance 
letter, and it runs directly counter to the 20-year history of industry 
reliance on the FDA's initial position.'' (285 Fed. Appx. at 811).
    The district court's preliminary injunction, as affirmed by the 
circuit court, halted FDA's implementation of the requirements of Sec.  
203.50(a). Specifically, the order enjoins FDA from implementing the 
requirement in Sec.  203.50(a) that a pedigree identify each prior sale 
or trade of a drug back to the drug's original manufacturer and the 
requirement that specifies the types of information that must be 
included in the pedigree, including lot numbers and container sizes.
    Under the district court's order, unauthorized distributors are 
only required to provide pedigrees that include information regarding 
transactions going back to either the manufacturer or the last 
authorized distributor of record that handled the drugs. In addition, 
as specified in the FD&C Act, all pedigrees must include the dates of 
the listed transactions and the names and addresses of all parties to 
those transactions. We recognized that these circumstances resulting 
from the court's order could lead to confusion and possible disruptions 
or delays in the nation's drug distribution system for wholesale 
distributors operating outside of the court's jurisdiction and could 
provide an undue advantage to certain wholesaler distributors. 
Therefore, we announced that we would exercise enforcement discretion 
in a manner consistent with the court's opinion throughout the rest of 
the country.

II. Proposed Regulation

    FDA is now proposing to remove Sec.  203.50(a). Over the past 20 
years, we have endeavored to ensure that the pedigree requirements in 
our regulations are consistent with congressional intent and provide 
appropriate accountability to protect our nation's drug supply. We have 
made a good faith effort to implement the requirements in Sec.  
203.50(a) consistent with the language of the PDMA through public 
meetings, Federal Register documents requesting comments, meetings with 
the wholesale industry, Members of Congress, and others, a Report to 
Congress, and other actions. For the various reasons discussed earlier, 
Sec.  203.50(a) has been effective for only a total of 7 days since the 
finalization of the rule in 1999. As explained previously, there have 
been serious ongoing concerns about the

[[Page 41437]]

effect that full implementation of the statutory pedigree requirements, 
as codified in Sec.  203.50(a), would have on the nation's drug supply 
and on wholesaler distributors. Therefore, in light of the courts' 
opinions, we are proposing to remove Sec.  203.50(a).
    By proposing to remove Sec.  203.50(a), we would remove the 
requirement in the regulation that the pedigree identify each prior 
sale or trade of a drug back to the drug's manufacturer. In addition, 
this proposal would remove the requirement in the regulation that the 
identifying statement include certain information, such as the 
proprietary and established name of the drug, the dosage, container 
size, number of containers, the drug's lot or control number(s), the 
business name and address of all parties for each prior transaction, 
starting with the manufacturer, and the date of each previous 
transaction. While the rulemaking to remove the regulation is pending, 
we intend to exercise enforcement discretion with respect to all of 
these requirements in Sec.  203.50(a).
    We note that even with the removal of Sec.  203.50(a), the pedigree 
requirements of section 503(e)(1)(A) of the FD&C Act would still be in 
effect. However, with respect to these statutory pedigree requirements, 
the Agency intends to exercise enforcement discretion and not initiate 
an enforcement action against any wholesalers for failing to provide a 
pedigree that goes back to the manufacturer or for failing to include 
the specific information listed in the regulation, as long as the 
pedigree otherwise identifies the last authorized distributor of record 
that handled the drugs and the associated dates of the transactions, as 
well as the names and addresses of all unauthorized distributors that 
handled the drug after the last authorized distributor, and the 
corresponding dates of those transactions.
    In summary, unauthorized distributors need to be aware that their 
pedigree(s) must: (1) Include information regarding transactions going 
back to either the manufacturer or the last authorized distributor of 
record that handled the drugs, consistent with the preliminary 
injunction order previously referenced and (2) include the date of the 
transaction and the names and addresses of all parties to the 
transaction as explicitly required under section 503(e)(1)(A) of the 
FD&C Act. Furthermore, while FDA is proposing to remove Sec.  203.50(a) 
and intends to exercise enforcement discretion under these described 
circumstances with respect to the statutory requirements for a 
pedigree, FDA encourages wholesalers to include the drug, dosage, 
container size, number of containers, and the drug's lot or control 
number(s) in the pedigree as well.
    FDA continues to believe that drug supply chain security is of the 
utmost importance and that transparency of transactions and 
accountability are essential to further secure our nation's drug 
supply. Counterfeit and diverted drugs continue to be found in our drug 
supply chain and the action proposed in this document should not be 
interpreted to mean that there is not a problem with counterfeit and 
diverted drugs. Rather, FDA remains committed to the framework set 
forth in the 2004 FDA Counterfeit Drug Task Force Report (Task Force 
Report) and subsequent updates to that Task Force Report (http://www.fda.gov/Drugs/DrugSafety/ucm169825.htm) and will continue to move 
forward, working with the private and public sectors to improve the 
security of the drug supply chain and implement measures to further 
protect Americans from counterfeit and diverted drugs. We also will 
continue our efforts to implement the pharmaceutical security 
provisions contained in section 913 of the Food and Drug Administration 
Amendments Act of 2007.
    As stated in the Task Force Report, such measures include 
implementation of tracking and tracing, which would help secure the 
integrity of the supply chain by providing an accurate electronic 
record of transactions in the drug supply chain. Such electronic 
records documenting the movement of a drug product from the 
manufacturer to the dispenser would be an important step in preventing 
counterfeit and diverted drugs from entering the drug supply chain. FDA 
will continue to develop standards for the purpose of securing the drug 
supply chain against counterfeit, diverted, subpotent, substandard, 
adulterated, misbranded, or expired drugs, including standards for the 
identification, validation, authentication, and tracking and tracing of 
prescription drugs. We are not proposing any new provisions in lieu of 
Sec.  203.50(a) at this time.

III. Legal Authority

    FDA is issuing this proposed rule to remove the provisions in Sec.  
203.50(a) under its rulemaking authority under section 701(a) of the 
FD&C Act (21 U.S.C. 371) and based on those reasons provided in section 
II of this document. Specifically, FDA can issue regulations through 
its rulemaking authority to establish requirements for section 503(e) 
of the FD&C Act. As described in section I of this document, FDA 
previously issued a final rule establishing certain requirements for 
section 503(e)(1)(a). Similarly, under its rulemaking authority, FDA 
can propose to remove those specific requirements that have been 
established by regulation. FDA is basing the proposed removal of Sec.  
203.50(a) on the grounds described in section II of this document. As 
explained earlier, the statutory provisions of section 503(e) of the 
FD&C Act, as well as the other provisions of Sec.  203.50 that would 
not be removed by this proposed rule, would remain legally effective.

IV. Analysis of Impacts

    FDA has examined the impacts of the proposed rule under Executive 
Order 12866, Executive Order 13563, the Regulatory Flexibility Act (5 
U.S.C. 601-612), and the Unfunded Mandates Reform Act of 1995 (Pub. L. 
104-4). Executive Orders 12866 and 13563 direct Agencies to assess all 
costs and benefits of available regulatory alternatives and, when 
regulation is necessary, to select regulatory approaches that maximize 
net benefits (including potential economic, environmental, public 
health and safety, and other advantages; distributive impacts; and 
equity). The Agency believes that this proposed rule is not a 
significant regulatory action as defined by Executive Order 12866.
    The Regulatory Flexibility Act requires Agencies to analyze 
regulatory options that would minimize any significant impact of a rule 
on small entities. Because the removal of the specified pedigree 
requirements for prescription drug distribution in Sec.  203.50(a) 
would not measurably decrease the estimated compliance costs of the 
December 1999 final rule, the Agency proposes to certify that the final 
rule will not have a significant economic impact on a substantial 
number of small entities.
    Section 202(a) of the Unfunded Mandates Reform Act of 1995 requires 
that Agencies prepare a written statement, which includes an assessment 
of anticipated costs and benefits, before proposing ``any rule that 
includes any Federal mandate that may result in the expenditure by 
State, local, and tribal governments, in the aggregate, or by the 
private sector, of $100,000,000 or more (adjusted annually for 
inflation) in any one year.'' The current threshold after adjustment 
for inflation is $136 million, using the most current (2010) Implicit 
Price Deflator for the Gross Domestic Product. FDA does not expect this 
proposed rule to result in any 1-year expenditure that would meet or 
exceed this amount.

[[Page 41438]]

    The Agency published a final rule on December 3, 1999, codified in 
Sec.  203.50(a), that contained certain requirements concerning 
prescription drug distribution. Specifically, it required that before 
the wholesale distribution of any prescription drug to another 
wholesale distributor or retail pharmacy for which the seller is not an 
authorized distributor of record, the wholesale distributor must 
provide to the purchaser a statement identifying each prior sale, 
purchase or trade. Further, it contained a list of specific information 
to be contained in the identifying statement. As explained previously, 
this regulation is the subject of a preliminary injunction. In the 
December 1999 final rule, the Agency estimated that the wholesale 
distribution requirements, including the drug identifying (or origin) 
statement and a separate distributor list to be provided by 
manufacturers, would together impose $258,000 in annual recordkeeping 
costs. In making this estimate, the Agency judged that the marginal 
costs for the inclusion of the additional information that Sec.  
203.50(a) would have required beyond that information that would be 
required in the PDMA pedigree provision would be negligible, and did 
not increase its cost estimate to reflect this additional effort. The 
removal of Sec.  203.50(a), therefore, is expected to reduce compliance 
costs by only that negligible amount that the Agency did not separately 
estimate for the final rule, as the pedigree provision of the PDMA 
still requires its own, slightly less expansive, pedigree provision. 
This regulatory action that removes a provision of the December 1999 
final rule is expected to reduce the previously estimated annual 
compliance costs of $258,000 for this provision by a negligible, but 
unquantified, amount.

V. Paperwork Reduction Act of 1995

    FDA tentatively concludes that this proposed rule contains no 
collection of information. Therefore, clearance by the Office of 
Management and Budget under the Paperwork Reduction Act of 1995 is not 
required.

VI. Environmental Impact

    The Agency has determined under 21 CFR 25.30 this action is of a 
type that does not individually or cumulatively have a significant 
effect on the human environment. Therefore, neither an environmental 
assessment nor an environmental impact statement is required.

VII. Federalism

    FDA has analyzed this proposed rule in accordance with the 
principles set forth in Executive Order 13132. FDA has determined that 
the proposed rule, if finalized, would not contain policies that would 
have substantial direct effects on the States, on the relationship 
between the National Government and the States, or on the distribution 
of power and responsibilities among the various levels of government. 
Accordingly, the Agency tentatively concludes that the proposed rule 
does not contain policies that have federalism implications as defined 
in the Executive order and, consequently, a federalism summary impact 
statement is not required.

VIII. Proposed Effective Date

    The Agency is proposing that any final rule that may issue based 
upon this proposed rule become effective upon its publication in the 
Federal Register.

IX. Comments

    Interested persons may submit to the Division of Dockets Management 
(see ADDRESSES) either electronic or written comments regarding this 
document. It is only necessary to send one set of comments. It is no 
longer necessary to send two copies of mailed comments. Identify 
comments with the docket number found in brackets in the heading of 
this document. Received comments may be seen in the Division of Dockets 
Management between 9 a.m. and 4 p.m., Monday through Friday.

List of Subjects in 21 CFR Part 203

    Labeling, Prescription drugs, Reporting and recordkeeping 
requirements, Warehouses.

    Therefore, under the Federal Food, Drug, and Cosmetic Act and under 
authority delegated to the Commissioner of Food and Drugs, it is 
proposed that 21 CFR part 203 be amended as follows:

PART 203--PRESCRIPTION DRUG MARKETING

    1. The authority citation for 21 CFR part 203 continues to read as 
follows:


    Authority: 21 U.S.C. 331, 333, 351, 352, 353, 360, 371, 374, 
381.


Sec.  203.50  [Amended]

    2. Section 203.50 is amended by removing and reserving paragraph 
(a).

    Dated: July 1, 2011.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2011-17696 Filed 7-13-11; 8:45 am]
BILLING CODE 4160-01-P